KPTI — Karyopharm Therapeutics Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on KPTI
| date | signal | measured base rate |
|---|---|---|
| 2026-08-17 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-06-26 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-26 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-05-15 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-03-26 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-03-03 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-28 | Poulton Stuart EVP, Chief Development Officer | Open-market sale | 189 | 7.10 | 1.3K |
| 2026-05-21 | Greene Barry E Director | Grant or award | 15.5K | 0.00 | 0 |
| 2026-05-21 | BOHLIN GAREN G Director | Grant or award | 15.5K | 0.00 | 0 |
| 2026-05-21 | Schor Chen Director | Grant or award | 15.5K | 0.00 | 0 |
| 2026-05-21 | Oliger Christy J. Director | Grant or award | 15.5K | 0.00 | 0 |
| 2026-05-21 | Su Zhen Director | Grant or award | 15.5K | 0.00 | 0 |
| 2026-05-21 | PAKIANATHAN DEEPIKA Director | Grant or award | 15.5K | 0.00 | 0 |
| 2026-05-14 | Paulson Richard A. President and CEO | Open-market sale | 2.2K | 9.50 | 20.9K |
| 2026-05-14 | Rangwala Reshma EVP & Chief Medical Officer | Open-market sale | 408 | 9.50 | 3.9K |
| 2026-05-14 | Poulton Stuart EVP, Chief Development Officer | Open-market sale | 403 | 9.50 | 3.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Commodore Capital LP | 10.9M | 1.9M |
| RA CAPITAL MANAGEMENT, L.P. | 10.7M | 1.9M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10.1M | 1.8M |
| Avidity Partners Management LP | 6.4M | 927.5K |
| GOLDMAN SACHS GROUP INC | 5.3M | 947.6K |
| Catalio Capital Management, LP | 5.0M | 897.7K |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1M | 739.7K |
| Ikarian Capital, LLC | 4.1M | 733.4K |
| Affinity Asset Advisors, LLC | 2.8M | 500.0K |
| Soleus Capital Management, L.P. | 2.5M | 440.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-13 | 2026-08-13 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-12 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-11 | — | on EDGAR ↗ |
| 8-K | 2026-07-31 | 2026-07-30 | on EDGAR ↗ |
| 4 | 2026-07-30 | 2026-07-28 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI · 2026-08-20
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI · 2026-08-13
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI · 2026-08-13
- Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook · 2026-08-13
- Karyopharm Therapeutics Inc. (KPTI) filed form 8-K · 2026-08-13 · SEC EDGAR
- Karyopharm Therapeutics Q2 2026 Earnings Preview · 2026-08-12
Ask the AI about KPTI
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →